Ibandronic acid

Drug Profile

Ibandronic acid

Alternative Names: BM 210955; Bondronat; Boniva; Bonviva; CT-064; Ibandronate; Ibandronate sodium hydrate; Methylpentylaminopropylidene; R 484; RG484; RO 2005450; Ro200-5450; Ro200-5450iv; Ro200-5450po; RPR 102289A

Latest Information Update: 03 Feb 2017

Price : $50

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche; Taisho Pharmaceutical
  • Class Antihypercalcaemics; Bisphosphonates; Calcium regulators; Osteoporosis therapies; Small molecules
  • Mechanism of Action Bone resorption factor inhibitors; Dimethylallyltranstransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Malignant hypercalcaemia; Osteoporosis; Postmenopausal osteoporosis
  • Discontinued Cancer pain

Most Recent Events

  • 16 Sep 2016 Updated efficacy data from a phase III MOVEST trial in Oesteoporosis presented at the 38th Annual Meeting of the American Society for Bone and Mineral Research (ASBMR-2016)
  • 23 Aug 2016 Roche withdraws a phase II trial in Cancer pain in Greece (NCT00478270)
  • 21 Apr 2016 Launched for Osteoporosis in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top